drugset
drugset / Trial / NCT01902251

Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients

NCT01902251 ↗

Phase 1 Completed 27 enrolled Astellas Pharma Europe B.V. Medivation, Inc. · collab
RandomizedParallel-groupOpen-labelBasic science

Summary

A multiple dose relative bioavailability study in patients with prostate cancer comparing a capsule and a tablet formulation of enzalutamide.

Timeline

Start
2012-11
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Enzalutamide Other / unclassified 160 mg Oral

Indications

prostate cancer